|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.01 USD | +2.35% |
|
-1.96% | -4.94% |
Sept 11 (Reuters) - Moderna said on Monday it is collaborating with Immatics to develop cancer vaccines.
Immatics will get $120 million upfront cash as part of the agreement. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 108 USD | +1.69% | +6.47% | 41.34B | ||
| 10.01 USD | +2.35% | -1.96% | 1.03B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -4.94% | 1.03B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
IMMATICS N.V. 
